Tools and resources Tools to help you put the guidance into practice. Summary versions Treatment pathways interactive PDF of all treatment pathways for squamous and non-squamous advanced non-small-cell lung cancer PDF 719 KB 11 August 2022 Squamous pathway: No targetable mutations, PD-L1 less than 50% PDF 76 KB 11 August 2022 Squamous pathway: No targetable mutations, PD-L1 50% or more PDF 116 KB 11 August 2022 Squamous pathway: RET fusion positive, PD-L1 less than 50% PDF 80 KB 11 August 2022 Squamous pathway: RET fusion positive, PD-L1 50% or more PDF 119 KB 11 August 2022 Squamous pathway: NTRK fusion positive, PD-L1 less than 50% PDF 80 KB 11 August 2022 Squamous pathway: NTRK fusion positive, PD-L1 50% or more PDF 118 KB 11 August 2022 Squamous pathway: KRAS G12C positive, PD-L1 less than 50% PDF 81 KB 11 August 2022 Squamous pathway: KRAS G12C positive, PD-L1 50% or more PDF 119 KB 11 August 2022 Non-squamous pathway: No targetable mutations, PD-L1 less than 50% PDF 72 KB 11 August 2022 Non-squamous pathway: No targetable mutations, PD-L1 50% or more PDF 88 KB 11 August 2022 Non-squamous pathway: EGFR-TK positive PDF 105 KB 11 August 2022 Non-squamous pathway: ALK positive PDF 73 KB 11 August 2022 Non-squamous pathway: ROS-1 positive PDF 81 KB 11 August 2022 Non-squamous pathway: RET fusion positive, PD-L1 less than 50% PDF 84 KB 11 August 2022 Non-squamous pathway: RET fusion positive, PD-L1 50% or more PDF 100 KB 11 August 2022 Non-squamous pathway: NTRK fusion positive, PD-L1 less than 50% PDF 85 KB 11 August 2022 Non-squamous pathway: NTRK fusion positive, PD-L1 50% or more PDF 101 KB 11 August 2022 Non-squamous pathway: KRAS G12C positive, PD-L1 less than 50% PDF 85 KB 11 August 2022 Non-squamous pathway: KRAS G12C positive, PD-L1 50% or more PDF 100 KB 11 August 2022 Fully accessible Word version of all treatment pathways for squamous and non-squamous advanced non-small-cell lung cancer Word 46 KB 11 August 2022 Squamous fully accessible summary: No targetable mutations, PD-L1 less than 50% Word 32 KB 11 August 2022 Squamous fully accessible summary: No targetable mutations, PD-L1 50% or more Word 32 KB 11 August 2022 Squamous fully accessible summary: RET fusion positive, PD-L1 less than 50% Word 33 KB 11 August 2022 Squamous fully accessible summary: RET fusion positive, PD-L1 50% or more Word 32 KB 11 August 2022 Squamous fully accessible summary: NTRK fusion positive, PD-L1 less than 50% Word 33 KB 11 August 2022 Squamous fully accessible summary: NTRK fusion positive, PD-L1 50% or more Word 32 KB 11 August 2022 Squamous fully accessible summary: KRAS G12C positive, PD-L1 less than 50% Word 33 KB 11 August 2022 Squamous fully accessible summary: KRAS G12C positive, PD-L1 50% or more Word 33 KB 11 August 2022 Non-squamous fully accessible summary: No targetable mutations, PD-L1 less than 50% Word 33 KB 11 August 2022 Non-squamous fully accessible summary: No targetable mutations, PD-L1 50% or more Word 32 KB 11 August 2022 Non-squamous fully accessible summary: EGFR-TK positive Word 33 KB 11 August 2022 Non-squamous fully accessible summary: ALK positive Word 33 KB 11 August 2022 Non-squamous fully accessible summary: ROS-1 positive Word 33 KB 11 August 2022 Non-squamous fully accessible summary: RET fusion positive, PD-L1 less than 50% Word 33 KB 11 August 2022 Non-squamous fully accessible summary: RET fusion positive, PD-L1 50% or more Word 33 KB 11 August 2022 Non-squamous fully accessible summary: NTRK fusion positive, PD-L1 less than 50% Word 33 KB 11 August 2022 Non-squamous fully accessible summary: NTRK fusion positive, PD-L1 50% or more Word 33 KB 11 August 2022 Non-squamous fully accessible summary: KRAS G12C positive, PD-L1 less than 50% Word 33 KB 11 August 2022 Non-squamous fully accessible summary: KRAS G12C positive, PD-L1 50% or more Word 33 KB 11 August 2022 Algorithm for intrathoracic staging before radical treatment PDF 104 KB 28 March 2019 Implementation support Endorsed resource – PET-CT reporting training programme (lymphoma, head and neck cancer, lung cancer, oesophageal cancer modules) Measuring the use of NICE guidance: NICEimpact lung cancer Resource impact Resource impact statement Audit and service improvement Baseline assessment tool Excel 432 KB 28 March 2019 Related news Promising lung cancer treatment approved for Cancer Drugs Fund Research recommendations Research recommendations information Guidance into practice About the Into practice guide Practical steps to improving the quality of care and services using NICE guidance